Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles

• Main Authors: Wen Zhang (Author), Yihui Zhai (Author), Ying Cai (Author), Xiang Gong (Author), Yunxuan Jiang (Author), Rong Rong (Author), Chao Zheng (Author), Binyu Zhu (Author), Helen He Zhu (Author), Hao Wang (Author), Yaping Li (Author), Pengcheng Zhang (Author)
• Format: Book
• Published: Elsevier, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Current cytotoxic T lymphocyte (CTL) activating immunotherapy requires a major histocompatibility complex I (MHC-I)-mediated presentation of tumor-associated antigens, which malfunctions in around half of patients with triple-negative breast cancer (TNBC). Here, we create a LCL161-loaded macrophage...